Advanced Biomed Inc.

AI-generated fair value estimate for this company.

Method: Conservative adjusted net asset value as of the 10-Q for period ended 3/31/2026: cash $2,602,697 plus other current assets $2,038,455 plus a 50%-haircut on a $5,885,157 due-from-discontinued-operations receivable ($2,942,579, haircut applied given no disclosed collection timeline or allowance) plus $120,015 non-current assets, minus total liabilities $1,436,587, divided by 1,382,133 common shares outstanding post 1-for-20 reverse split.

Reasoning: ADVB is genuinely pre-revenue after divesting its Hong Kong clinical subsidiary, making a DCF unfounded since there is no revenue base to project; a net-asset floor value, haircut for the low-disclosure disposal receivable that makes up over half of current assets, is the most defensible grounded approach for this pre-commercial microcap.